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Cytosolic Phospholipase A2 Activation Correlates
with HER2 Overexpression and Mediates
Estrogen-Dependent Breast Cancer Cell Growth
Francesco Caiazza, Brian J. Harvey, and Warren Thomas
Department of Molecular Medicine, Royal College of Surgeons in Ireland, Education and Research
Centre, Beaumont Hospital, Dublin 9, Ireland
Cytosolic phospholipase A2 (cPLA2) catalyzes the hydrolysis of membrane glycerol-phospholip-
ids to release arachidonic acid as the first step of the eicosanoid signaling pathway. This pathway
contributes to proliferation in breast cancer, and numerous studies have demonstrated a crucial
role of cyclooxygenase 2 and prostaglandin E2 release in breast cancer progression. The role of
cPLA2 activation is less clear, and we recently showed that 17-estradiol (E2) can rapidly activate
cPLA2 in MCF-7 breast cancer cells. Overexpression or gene amplification of HER2 is found in
approximately 30% of breast cancer patients and correlates with a poor clinical outcome and
resistance to endocrine therapy. This study reports the first evidence for a correlation between
cPLA2 enzymatic activity and overexpression of the HER2 receptor. The activation of cPLA2 in
response to E2 treatmentwas biphasic with the first phase dependent on trans-activation through
the matrix metalloproteinase-dependent release of heparin-bound epidermal growth factor.
EGFR/HER2 heterodimerization resulted in downstream signaling through the ERK1/2 cascade to
promote cPLA2 phosphorylation at Ser505. There was a correlation between HER2 and cPLA2
expression in six breast cancer cell lines examined, and inhibition of HER2 activation or expression
in the SKBR3 cell line using herceptin or HER2-specific small interfering RNA, respectively, resulted
in decreased activation and expression of cPLA2. Pharmacological blockade of cPLA2 using a
specific antagonist suppressed the growth of both MCF-7 and SKBR3 cells by reducing E2-induced
proliferation and by stimulating cellular apoptosis and necrosis. This study highlights cPLA2 as a
potential target for therapeutic intervention in endocrine-dependent and endocrine-indepen-
dent breast cancer. (Molecular Endocrinology 24: 0000–0000, 2010)
The phospholipase A2 (PLA2) enzymes catalyze thehydrolysis of the sn-2 linkage in membrane glycer-
ol-phospholipids to release arachidonic acid (AA) and
lysophospholipid secondary messengers. AA is then con-
verted to bioactive eicosanoid lipid mediators such as
prostaglandins, lipoxins, and leukotrienes, which play
important regulatory roles in diverse cellular responses.
There are three PLA2 isoform subfamilies: the Ca
2-de-
pendent secretory PLA2, the Ca
2-independent intracel-
lular PLA2, and the Ca
2-dependent cytosolic PLA2
(cPLA2). The cPLA2 isoform is constitutively expressed
in most cells, and through the modulation of substrate
availability, cPLA2 regulates the rate of AA metabolism
to prostaglandins by cyclooxygenases (COX) and so in-
directly regulates prostaglandin E2 (PGE2) production (1,
2). The AA-based eicosanoid signaling pathway plays an
important role in normal cellular homeostasis, inflam-
mation, and pathophysiological conditions. Specifi-
cally, eicosanoid signaling has been implicated in the
development and progression of malignancy in different
tissues including the lung (3), colon (4), prostate (5), and
mammary gland (6). Overexpression of AA-metabolizing
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enzymes, principally COX-2, can be detected in many
breast tumors and correlates with poor patient prognosis
(7). COX inhibition decreases cell growth and promotes
chemotherapy-induced apoptosis in breast cancer cells
(8); epidemiological evidence also links the chronic use of
COX-2 inhibitors with a reduced risk of breast cancer
development (9, 10).
Recent data have suggested a link between eicosanoid
signaling and estrogen-stimulated signaling events in
breast cancer cells, at the level of both cPLA2 and
COX-2 activity (11). The eicosanoid pathway has a po-
tential role in estrogen-responsive breast cancer through a
positive feedback loop, where COX-2 transcription is up-
regulated by estrogen through epidermal growth factor
receptor (EGFR) trans-activation (12), and COX-2 activ-
ity stimulates aromatase activity with important conse-
quences for tumor cell proliferation (13). The mitogenic-
ity of circulatory estrogens exerts a critical effect on the
etiology and progression of breast cancer, where cumula-
tive exposure of the mammary epithelium to estrogens is
a significant risk factor (14, 15). The effects of estrogens,
including the most biologically active 17-estradiol (E2),
are driven through the specific estrogen receptors (ERs) 
and  (reviewed in Ref. 16). Antagonism of these recep-
tors serves as the basis for therapeutic intervention in
breast cancer using selective ER modulators (SERMs)
such as tamoxifen and fulvestrant (17–19). ERs act by
regulating gene transcription in the nucleus and by mod-
ulating the rapid activation of different signaling path-
ways from the plasma membrane (16). In particular,
rapid activation of ERK1/2 MAPK by E2 through ER
and EGFR trans-activation has been reported in breast
cancer cells (20).
Several studies have linked rapid estrogen-induced sig-
naling to EGFR trans-activation: Filardo and Thomas
(21) reported the involvement of the G protein-coupled
receptor (GPR)-30 in the activation ofmatrixmetallopro-
teinase (MMP), release of heparin-bound (HB)-EGF, and
activation of EGFR in SKBR3 breast carcinoma cells.
Razandi et al. (22, 23) demonstrated a direct interaction
between ER and G proteins and also found that this in-
teraction triggers a Gq andG-dependent activation of
MMPs leading to EGFR trans-activation and downstream
signaling to ERK and phosphatidylinositol 3-kinase in
breast cancer cells. These E2-induced indirect effects can
potentiate the mitogenic action of estrogens and are also
involved in the development of endocrine resistance by
diverting the effects of E2 to alternative growth factor
receptor signaling pathways that are insensitive to
SERMs (24). The dependency of growth on estrogens can
be circumvented by overexpression of EGFR/c-erbB1 and
HER2/c-erbB2 (members of the EGFR family of receptor
tyrosine kinases that also include c-erbB3 and c-erbB4),
which is frequently found in invasive breast cancer and
where it correlates with a decreased sensitivity to endo-
crine therapy and with poor patient prognosis (25).
Clinical, epidemiological, and molecular studies have
investigated the role of eicosanoid signaling in breast can-
cer, focusing mainly on COX-2 and its metabolite PGE2
(11, 26). Animal models have shown that carcinogen-
induced mammary tumor formation can be reduced by
either treatment with COX inhibitors (27–29) or genetic
ablation of Cox-2 (30). Conversely, COX-2 overexpres-
sion in mouse mammary gland increased tumor forma-
tion and potentiated angiogenesis (31, 32). As the major
prostaglandin produced by COX-2 in breast cancer (33),
PGE2 has been shown to play a key role in many aspects
of COX-2-induced tumorigenesis. PGE2 levels are ele-
vated in breast cancer (31), and in vitro studies have
shown that PGE2 can stimulate both the proliferation
(34) and migration (35) of mammary epithelial cells.
PGE2 can stimulate the expression of growth-promoting
genes such as c-fos and VEGF (36) and can also increase
aromatase activity and consequent estrogen biosynthesis
(13), indirectly contributing to cell proliferation.
Despite the body of data available on the role of COX-2
and PGE2 in breast cancer tumorigenesis, the role of cPLA2
in the cross talk between the estrogen and the eicosanoid
signaling pathways in estrogen-responsive breast cancer re-
mains unclear. cPLA2 is involved in the rapid estrogen-in-
duced responses in the colon (37) and in embryonic mem-
branes (38). Previous work from our laboratory showed
that low concentrations of E2 rapidly promote the activa-
tion of cPLA2 in theMCF-7 breast cancer cell line, impact-
ing on the rapid, estrogen-driven transient rise in intracellu-
lar Ca2 concentration. cPLA2 was activated through
ERK1/2MAPK-dependent phosphorylation on Ser505 and
intracellular translocation to perinuclear membranes (39).
Here we have identified the receptors and characterized the
molecular mechanisms involved in the rapid estrogen-in-
duced activation of cPLA2 in both endocrine-sensitive and
endocrine-resistant breast cancer cells.
Results
E2 rapidly and transiently stimulates cPLA2
phosphorylation through ER-dependent ERK1/2
activation in MCF-7 cells
We previously showed that E2 stimulated the phos-
phorylation of cPLA2 at residue Ser505 within 1 min of
treatment inMCF-7 cells (39). To further characterize the
the E2-induced cPLA2 response, we analyzed a time
course ranging from 30 sec to 20min. E2 (10 nM) induced
a rapid, transient, and biphasic activation of cPLA2,
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with a first peak of phosphorylation starting as early as 30
sec to 2 min after treatment and a second peak detectable
from 4–15 min after treatment (Fig. 1A). Time points
corresponding to the two maximal peaks of activation
(1 and 10 min) were chosen for analysis in all subsequent
experiments. The rapid E2-induced activation of signal-
ing pathways is thought to be mediated by an ER local-
ized at or near the plasma membrane. The nature of such
a receptor has variously been reported to be either a trun-
cated form of ER, a lipid-modified form of ER, or a
GPR like GPR30 (40). We previously showed that the
rapid activation of cPLA2 can be induced by both E2 and
the membrane-impermeable E2-BSA (39), indicating the
involvement of a membrane-localized receptor. Here we
show that the specific ER antagonist ICI 182,780 (ICI)
blocked the E2-induced phosphorylation of cPLA2 at
both 1- and 10-min time points (Fig. 1B).
Phosphorylation of cPLA2 at Ser505 is mediated by
members of theMAPK family (2), and inMCF-7 cells, the
rapid effect of E2 on cPLA2 is specifically driven through
ERK1/2 (39). The specific MAPK kinase-1 inhibitor
PD98059 blocked the E2-induced phosphorylation of
cPLA2 at 1 and 10 min (Fig. 1B), thus confirming the
involvement of ERK1/2 MAPK upstream of cPLA2. In-
terestingly, E2 promotes a transient and biphasic phos-
phorylation of ERK1/2 in MCF-7 cells that mirrors the
time-course for cPLA2 activation (39). Because E2 can
activate MAPK through trans-activation of EGFR (41,
42), we investigated the role of EGFR inmediating the stim-
ulatory effect of E2on cPLA2. Pretreatment ofMCF-7 cells
with the specific EGFR/HER2 inhibitor AG825 blocked
the first rapid peak of E2-induced cPLA2 phosphoryla-
tion but only partially suppressed the subsequent activa-
tion at 10 min (Fig. 1B). AG825 is an EGFR kinase inhib-
itor preferentially selective for HER2 over EGFR,
suggesting that HER2 may play a greater role in the ear-
lier phase of cPLA2 activation.
Rapid E2-induced cPLA2 activation is dependent
on trans-activation of EGFR-HER2 heterodimers
Recent evidence demonstrates that in breast cancer
cells, E2 promotes EGFR trans-activation and down-
stream signaling through the c-Src-mediated activation of
the MMP cascade and the subsequent release of mem-
brane-associated HB-EGF (23, 42). MCF-7 cells were
pretreated with the diphtheria toxin mutant CRM197,
which inhibits the mitogenic activity of HB-EGF by
promoting its internalization from the cell membrane
(43). CRM197 blocked E2-induced phosphorylation of
cPLA2 after 1 min treatment but achieved only partial
inhibition of E2-induced cPLA2 phosphorylation at 10
min (Fig. 2A). CRM197 also blocked the E2-induced ac-
tivation of ERK1/2 upstream of cPLA2 at 1 min, but
inhibition was not observed at 10 min. (Fig. 2B). More-
over, pretreating MCF-7 cells with the general MMP in-
hibitor GM6001 blocked the E2 effect on cPLA2 phos-
phorylation at 1 min (Fig. 2C). These data demonstrate
that E2-induced cPLA2 activation at 1 and 10 min is
differentially regulated, with the early phase of cPLA2
activation being dependent on the activation of a MMP
cascade at the cell membrane leading to trans-activation
of EGFR. The later phase of E2-induced cPLA2 activa-
tion at 10 min was largely independent of EGFR trans-
activation. E2-bound ER binds to and activates the c-Src
tyrosine kinase, leading to MAPK activation, through
EGFR trans-activation or via direct activation of Ras (23,
42, 44). Pretreatment of MCF-7 cells with the specific
c-Src inhibitor 4-amino-5-(4chorophenyl)-7-(t-butyl)
pyrozolo[3,4-D]pyrimidine (PP2) blocked the E2-induced
activation of cPLA2 at both 1 and 10 min (Fig. 2D), thus
confirming the involvement of c-Src in the rapid activation
FIG. 1. E2 induces transient phosphorylation of cPLA2 through ER-
and EGFR-dependent MAPK activation. A, Western blot analysis of
phospho-cPLA2 (Ser505) and total cPLA2 was performed on MCF-7
cells treated with either vehicle (0) or 10 nM E2 at the indicated time
points. A representative blot is shown along with densitometric
analysis of three independent experiments. B, Western blot analysis of
phospho-cPLA2 (Ser505) and total cPLA2 was performed on MCF-7
cells treated for 1 and 10 min with either vehicle controls or E2 (10 nM)
with or without the inhibitors ICI (10 M), AG825 (5 M), or PD98059
(20 M). -Actin was used for protein level normalization.
Densitometric analysis of three independent experiments is shown with
a representative blot. Data are mean values  SE. *, P  0.01
compared with vehicle-treated control; °, P  0.01 compared with E2-
stimulated values at corresponding time points.
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of the MMP cascade leading to the EGFR-dependent early
phase of cPLA2 activation at 1 min. Pretreatment of
MCF-7 cellswithPP2alsoblocked the activationofERK1/2
after10minE2 treatment (Fig. 2E).Thesedata suggest that the
later phase of cPLA2 activation at 10min is largely driven by
a c-Src-mediated direct activation of the MAPK cascade that
augments the contribution of EGFR trans-activation.
EGFR and HER2 can form homodimers and het-
erodimers with each other and with the other two mem-
bers of the EGFR family (45). Receptor dimerization and
activation leads to trans-phosphorylation of specific ty-
rosine residues within the cytoplasmic tail of the recep-
tors. Activation of EGFR/HER2 heterodimers has been
observed in breast cancer cells, resulting in the activation
of distinct signaling pathways (46). E2 treatment pro-
moted tyrosine phosphorylation of EGFR in MCF-7 cells
within 1 min of treatment (Fig. 3A). The effect was per-
sistent for at least 10 min and abrogated by pretreatment
with CRM197, confirming that in this cell line, E2 pro-
motes EGFR trans-activation through release ofHB-EGF.
E2 treatment did not increase phosphorylation of HER2
above basal levels in MCF-7 cells (Fig. 3B), as compared
with HCC38 (used here as HER2-negative control) and
SKBR3 (HER2-overexpressing positive control). Coim-
munoprecipitation studies showed that E2 treatment in-
creased the basal level of association between EGFR and
HER2 within a rapid time frame of 1–3 min, correspond-
ing to the first peak of activation of cPLA2 (Fig. 3C). The
effect was also blocked by pretreatment with CRM197.
These data suggest that E2 induces a MMP-mediated re-
lease of HB-EGF acting in an autocrine fashion to pro-
mote trans-activation of EGFR through an increase in
active EGFR/HER2 heterodimers.
Increased cPLA2 expression and activity in
HER2-overexpressing breast cancer cell lines
To determine whether there was a correlation between
EGFR/HER2 heterodimerization and the activation of
FIG. 2. E2 activates cPLA2 through MMP- and HB-EGF-dependent trans-activation of EGFR. A and B, Western blot analysis of cPLA2
phosphorylation at residue Ser505 (A) and ERK1/2 MAPK phosphorylation at residues Thr202/Tyr204 (B) was performed on MCF-7 cells treated
with either vehicle (0) or 10 nM E2, with or without CRM197 (200 ng/ml, 2 h pretreatment) at the indicated time points. A line separates
noncontiguous lanes on the same gel. C, Phosphorylation of cPLA2 at residue Ser505 was assessed by immunoblotting in MCF-7 cells treated
with either vehicle (control) or 10 nM E2 for 1 min, with or without the MMP inhibitor GM6001 (10 M). D, Phosphorylation of cPLA2 at residue
Ser505 was assessed by immunoblotting in MCF-7 cells treated with either vehicle (0) or 10 nM E2 for 1 and 10 min, with or without the c-Src
antagonist PP2 (100 nM). E, Phosphorylation of ERK1/2 at residues Thr202/Tyr204 was assessed by immunoblotting in MCF-7 cells treated with
either vehicle (0) or 10 nM E2 for 10 min, with or without the c-Src antagonist PP2 (100 nM). All blots were stripped and reprobed with total cPLA2
or total ERK1/2 MAPK antibodies. Total cPLA2 or total ERK1/2 was used for protein level normalization as appropriate. Densitometric analysis of
three independent experiments is shown with a representative blot. Data are mean values  SE. *, P  0.01 compared with E2 stimulation.
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cPLA2, we used the SKBR3 cell line, a breast cancer cell
line that is ER negative but HER2 positive and is used as
a model for endocrine-resistant, HER2-overexpressing
ductal breast carcinoma. Semiquantitative RT-PCR anal-
ysis confirmed that SKBR3 cells expressed significantly
higher levels of HER2 mRNA compared with MCF-7
cells (53  11% increase, P  0.001). cPLA2 mRNA
levels were also greater (30 4.9%, P 0.01) in SKBR3
cells compared with MCF-7, whereas no significant dif-
ference was measured in EGFR (17.5  2.8%) and
COX-2 (9.5  1.2%) mRNA levels (Fig. 4A). Western
blot analysis confirmed that protein expression levels
for EGFR (6.3-fold, P  0.001), HER2 (4.2-fold, P 
0.01), and cPLA2 (12.9-fold, P  0.001) were also
greater in SKBR3 cells compared with MCF-7 cells.
COX-2 expression was also slightly higher (1.4-fold) but
was not statistically significant (Fig. 4B). Quantitative
real-time PCR confirmed mRNA expression levels of
both HER2 and cPLA2 were significantly higher in
SKBR3 cells when compared with MCF-7 cells (Fig. 4C).
To address the question of whether the increased expres-
sion of cPLA2 in SKBR3 cells was coupled to an in-
creased enzymatic activity, we measured hydrolysis of the
substrate arachidonoyl thio-phosphatidylcholine in vitro
(Fig. 4D). SKBR3 cells showed a 2-fold greater cPLA2
catalytic activitywhen comparedwithMCF-7 cells (9.9
0.2vs.5.80.3nmol/minml, respectively), confirming that
the greater expression of cPLA2 in SKBR3 cells translates
into a higher enzymatic activity to drive production of AA.
To investigate whether the correlation between HER2 and
cPLA2 is a peculiar characteristic of the SKBR3cell line,we
compared a panel of five breast cancer cell lines that differ-
entially expressed HER2 with MCF-7 cells for both HER2
and cPLA2 mRNA (Fig. 5A) and protein (Fig. 5B) abun-
dance. All cell lines reported to be HER2 overexpressing
(BT474, SKBR3, and UACC893) (47) showed higher levels
of HER2 expression when compared with MCF-7 cells, at
both the mRNA and protein level. SKBR3 and UACC893
also showed higher levels of cPLA2 mRNA and protein
FIG. 3. E2 promotes activation of EGFR-HER2 heterodimers. MCF-7 cells were treated with either vehicle (0) or 10 nM E2 with or without
CRM197 (200 ng/ml) at the indicated time points. A and C, Lysates were immunoprecipitated with 2 g EGFR antibody and blotted for
phosphotyrosines (A) or immunoprecipitated with 2 g of either EGFR or HER2 antibody and blotted for HER2 and EGFR (C). Data are mean
values  SE. *, P  0.05 compared with E2 stimulation without CRM197 at corresponding time points. B, HCC38 (HER2-negative control breast
cancer cell line), MCF-7, and SKBR3 cells were treated with either vehicle (0) or 10 nM E2 at indicated time points, and lysates were subjected to
ELISA for phospho-HER2 (Tyr 1221/1222). The lower panel shows a representative Western blot of MCF-7 lysates immunoprecipitated with 2 g
HER2 antibody and blotted for phosphotyrosines. IP, Immunoprecipitation; WB, Western blot.
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compared with MCF-7 cells. BT474 cells had less
mRNA but the same amount of cPLA2 protein as com-
pared with MCF-7 cells. The two cell lines reported to
be nonoverexpressing (HCC38 and MDA-MB-231)
(47) expressed HER2 mRNA at comparable levels to
MCF-7 cells; both of these cell lines also expressed
higher levels of cPLA2 mRNA and protein compared
with MCF-7 cells (Fig. 5).
Inhibition of HER2 impacts on cPLA2 activation in
SKBR3 cells
The coupling of HER2 to cPLA2 activation in SKBR3
cells was investigated by studying the effect of HER2 in-
hibition on the expression and activation of cPLA2. To
do so, we used both a pharmacological inhibition ap-
proach using herceptin and a gene silencing approach
using small interfering RNA (siRNA). Herceptin (Trastu-
zumab) is a recombinant humanized monoclonal anti-
body directed against the extracellular domain of HER2
that is extensively used in the clinical setting to treat
HER2-positive metastatic breast cancer (48). The mech-
anism of action of herceptin is still not completely clear,
but several reports suggest that its action could be ex-
plained by an induced impairment of HER2 heterodimer-
ization and consequent blockade of downstream signal-
ing events (48). Treatment of SKBR3 cells with 20 g/ml
herceptin in the presence of serum for 48 h resulted in
inhibition of HER2 phosphorylation, with no change in
total HER2 protein expression (49). We found that treat-
ing cells with herceptin (20 g/ml) in the presence of E2
(10 nM) resulted in a similar inhibition of HER2 phos-
phorylation to that found for herceptin in the presence of
serum, with no change in total HER2 protein expression
levels (Fig. 6A). The reduction in HER2 phosphorylation
upon treatment with herceptin in conjunction with E2
was coupled to a reduction in cPLA2 phosphorylation,
FIG. 4. The endocrine-resistant breast cancer cell line SKBR3 overexpresses EGFR/HER2 and shows increased expression and activity of cPLA2.
A and C, Total mRNA was extracted from untreated MCF-7 and SKBR3 cells, reverse transcribed into cDNA, and either subjected to
semiquantitative PCR using specific primers for EGFR, HER2, cPLA2 and COX-2 (expression levels were normalized for GAPDH (a representative
agarose gel is shown along with densitometric analysis of six experiments) (A) or subjected to real-time quantitative PCR with specific primers for
HER2 and cPLA2 (C). mRNA expression levels were normalized to 18S and expressed as fold difference in relative quantity relative to MCF-7. Data
are mean values  SE. *, P  0.001; **, P  0.01 compared with MCF-7 values. B, Western blot analysis of total EGFR, HER2, cPLA2, and COX-2
was performed on unstimulated MCF-7 and SKBR3 cells. -Actin was used for protein level normalization. Densitometric analysis of three different
experiments is shown with a representative blot. Data are mean values  SE. *, P  0.001; **, P  0.01 compared with MCF-7 values. D, cPLA2
enzymatic activity was measured in total lysates from MCF-7 and SKBR3 cells. *, P  0.01 compared with MCF-7 values.
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with no change in total cPLA2 protein abundance (Fig.
6A). Treatment with either herceptin alone or E2 alone
did not change total expression or the phosphorylation
states of either HER2 or cPLA2.When SKBR3 cells were
transfected with a pool of four different siRNA species
specific for HER2, expression of the receptor was par-
tially silenced, with protein expression levels reduced to
30% of nontransfected control. Silencing of HER2 re-
duced cPLA2 protein expression to 58% of nontrans-
fected control and cPLA2 phosphorylation levels to
43% of nontransfected control (Fig. 6B), confirming the
positive correlation between HER2 overexpression and
the abundance of activated cPLA2 in SKBR3 cells. To
rule out any non-sequence-specific effects of gene silenc-
ing, a negative nontargeting siRNA control was used that
is designed to have at least four mismatches with all
known human genes. This negative siRNA had no effect
on the expression levels of HER2 or cPLA2, confirming
the specificity of cPLA2 down-regulation after selective
HER2 silencing (Fig. 6B). The HER2 siRNA did not
change cPLA2 expression at the mRNA level as com-
pared with nontransfected or negative siRNA-transfected
controls (Fig. 6C), indicating that HER2 exerts a post-
translational control of cPLA2 protein expression.
E2 rapidly promotes cPLA2 phosphorylation in
SKBR3 cells through GPR30-dependent
EGFR trans-activation
In the HER2-positive SKBR3 cells, cPLA2 was over-
expressed and was also constitutively activated (Figs. 4
and 6). However, E2 still promoted cPLA2 activation
above basal levels of phosphorylation, at both 1 and 10
min (Fig. 7A). This effect was blocked by pre-
treatment with CRM197, demonstrating that
the effect of E2 is driven by EGFR trans-acti-
vation in both ER-positive (MCF-7) and ER-
negative (SKBR3) cell lines (Fig. 7A). Unlike in
MCF-7 cells, CRM197 treatment fully blocked
E2-induced phosphorylation of cPLA2 in
SKBR3 cells at both 1 and 10 min. Pretreat-
ment with the selective EGFR/HER2 inhibitor
AG825 also blocked the E2-induced activation
of cPLA2 at 10 min (Fig. 7B). The effect of E2
on ERK1/2 activation showed a different tem-
poral activation profile in SKBR3 to that in
MCF-7 cells. In SKBR3 cells, ERK activation
started 1 min after E2 stimulation and in-
creased to a maximum at 5 min, remaining
constant for at least 10 min, in contrast to the
biphasic response observed in MCF-7 cells.
CRM197 blocked the stimulation of ERK1/2
activation by E2 in SKBR3 cells over the entire
duration of a 10-min time course (Fig. 7D),
whereas CRM197 completely blocked only the first tran-
sient phase of ERK activation in MCF-7 cells (Fig. 2A).
SKBR3 cells are described as ER negative as well as being
HER2 positive, but they do express GPR30, which binds
E2 to activate MAPK through MMP-mediated EGFR
trans-activation (42). The rapid effect of E2 on cPLA2
activation in SKBR3 cells was mimicked by the selective
GPR30 agonist G1 and by ICI, which also acts as a
GPR30 agonist (21). The effects of E2, G1, and ICI were
nonadditive, indicating that E2 and GPR30 agonists may
act through a common receptor and signaling pathway in
SKBR3 cells (Fig. 7C). The physiological role of GPR30
and its capacity to bind to and mediate the effects of E2
are still controversial.
Researchers have reported the expression of differen-
tially spliced ER isoforms, namely ER46 (50) and
ER36 (51), which inhibit the transcriptional activity of
wild-type ER and which could mediate the transduction
of estrogen- and antiestrogen-mediated mitogenic signal-
ing from the plasma membrane of endothelial and breast
cancer cells (52–54).Western blotting with a specific ER
antibody showed that SKBR3 cells do not express the
66-kDa wild-type ER, but two bands of approximately
36 and 46 kDa were present that were also detected in
MCF-7 cells (Fig. 8A). These bands could represent deg-
radation products, or alternatively spliced receptor iso-
forms with a similar molecular mass. However, the anti-
body that was used in this study is directed against an
epitope surrounding Ser118 in the A/B domain of ER, a
region that is completely deleted in the ER36 and ER46
isoforms (Fig. 8B). Furthermore, when SKBR3 cells were
FIG. 5. Analysis of HER2 and cPLA2 expression in a panel of breast cancer cell lines.
A, Total mRNA was extracted from untreated HCC38, MDA-MB-231, MCF-7,
BT474, SKBR3, and UACC893 cells, reverse-transcribed into cDNA, and subjected to
real-time quantitative PCR with specific primers for HER2 and cPLA2. mRNA
expression levels were normalized to 18S and expressed as fold difference in relative
quantity relative to MCF-7. B, Western blot analysis of total HER2 and cPLA2 was
performed on unstimulated HCC38, MDA-MB-231, MCF-7, BT474, SKBR3, and
UACC893 cells. -Tubulin was used for protein level normalization.
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grown in the presence of E2 for 24 h, the 46-kDa band
was not present, and the 36-kDa band was reduced com-
pared with cells grown in the absence of E2 (Fig. 8A). To
establish whether the mitogenic effects of E2 (namely,
activation of ERK1/2 MAPK and subsequently cPLA2)
in the SKBR3 cells were mediated by GPR30, we per-
formed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assays to study cell growth (Fig.
8C). Treatment with the antiestrogens ICI and tamoxifen,
both of which have been shown to act as GPR30 agonists
(21), mimicked the E2-induced increase in cell growth
with no additive effect. The selective GPR30 agonist G1
also increased cell growthwith no additive effects with E2
(Fig. 8C), suggesting that G1 and E2 were acting through
a common receptor to promote cell growth.
Antagonism of cPLA2 inhibits E2-induced cell
proliferation in MCF-7 and SKBR3 cells
The proliferative effect of E2 and EGFR ligands on
breast cancer cells is well characterized (16, 25); to inves-
tigate whether the eicosanoid signaling pathway and spe-
cifically cPLA2 activation is involved in these proliferative
events, we measured E2-induced cell growth using the
MTT cell growth assay in MCF-7 and SKBR3 cells pre-
treated with a specific cPLA2 inhibitor (Fig. 9). Treatment
ofMCF-7 cells with 10 nM E2 resulted in an increased cell
growth (24% increase compared with vehicle control).
Pharmacological inhibition of cPLA2 completely abol-
ished the E2-stimulated cell growth. This effect of cPLA2
inhibition on cell growth was comparable to growth in-
hibition after ICI treatment, which blocked the effect of
E2, reducing growth levels (Fig. 9A). In SKBR3 cells, E2
(10 nM) induced a 35% increase in cell growth compared
with vehicle-treated control. Pharmacological inhibition
of cPLA2 blocked the cell growth effect of E2 and re-
stored growth levels to control levels. Inhibition of HER2
with herceptin also down-regulated E2-stimulated cell
growth to control levels (Fig. 9B). In addition to inhibiting
the E2-induced cell growth, the cPLA2 inhibitor also
FIG. 6. Inhibition of HER2 in SKBR3 cells decreases cPLA2 activation and expression. Panel A, SKBR3 cells were treated with 20 g/ml herceptin
for 48 h with or without 10 nM E2 as indicated. Western blot analysis of phospho-cPLA2, total cPLA2, phospho-HER2, and total HER2 was
performed. -Actin was used for protein level normalization, and densitometric values are expressed as fold difference vs. vehicle-treated controls.
Data are mean values  SE. *, P  0.01 compared with control values. Panels B and C, SKBR3 cells were transfected with 100 nM of a pool of four
different siRNA targeting HER2. Negative control cells were transfected with 100 nM nontargeting siRNA. At 72 h after transfection, total proteins
and mRNA were extracted and subjected to either Western blot analysis for total HER2, phospho-cPLA2 (Ser505) and total cPLA2, (total cPLA2
was used for protein level normalization (panel B) (data are mean values  SE; *, P  0.001 compared with vehicle-treated control) or
semiquantitative RT-PCR using specific primers for cPLA2 (panel C) (expression levels were normalized for GAPDH, and a representative agarose gel
is shown along with densitometric analysis of two experiments). C, Control.
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reduced MCF-7 cell numbers below control basal levels,
which implied a homeostatic role for cPLA2 in regulat-
ing cell viability. Treatment of both MCF-7 and SKBR3
cell lines with the specific cPLA2 inhibitor increased the
incidence of both apoptotic and necrotic cell death com-
pared with vehicle-treated controls (Fig. 9C). In MCF-7
cells, the cPLA2 inhibitor caused an 85% increase in
apoptosis compared with control and a 2.4-fold increase
in necrosis. Tamoxifen was used as a positive control,
because its effect on cell death in MCF-7 has been previ-
ously reported (55). In SKBR3 cells, the inhibition of
cPLA2 caused a 2.6-fold increase in apoptosis and a 2.4-
fold increase in necrosis, compared with control. Inhibi-
tion of HER2 with herceptin, which has been shown to
induce cell death (48), also increased cell necrosis and
apoptosis in SKBR3 cells, and this response was similar to
that observed with the cPLA2 inhibitor (Fig. 9C).
Discussion
The activation of cPLA2 is the rate-limiting step in the
physiological production of AA, which is rapidly metab-
olized by COX enzymes to produce PGE2 (1). Prostaglan-
dins regulate many physiological processes through GPR
activation leading to the production of secondmessengers
that induce proliferation, migration, apoptosis, and an-
giogenesis (56). In addition, cPLA2 can also promote
carcinogenesis by liberating membrane lysophospholip-
ids that can induce cell growth through their metabolism
to lysophosphatidic acid (57). Consequently, cPLA2 ac-
tivity is tightly controlled to maintain low intracellular
concentrations of AA in resting cells. However, dysregu-
lation of cPLA2 activity is detected in many human ma-
lignancies, including mammary adenocarcinoma (6). In-
creased cPLA2 activity, coupled to increased activity of
AA-metabolizing enzymes such as COX-2, leads to high
FIG. 7. E2 increases the basal activation of cPLA2 in SKBR3 cells, acting through GPR30-mediated EGFR trans-activation. A–C, Western blot
analysis of phospho-cPLA2 (Ser505) and total cPLA2 was performed on SKBR3 cells treated with either vehicle (0) or E2 (10 nM), with or without
CRM197 (200 ng/ml) at the indicated time points (A); treated with vehicle (0) or E2 (10 nM), with or without AG825 (5 M) for 10 min (B); or
treated with vehicle (C) or E2 (10 nM) or ICI (10 mM) or the GPR30-selective agonist G1 (100 nM) for 10 min (C). A line separates noncontiguous
lanes on the same gel. Data are mean values  SE. **, P  0.01 compared with vehicle-treated control; *, P  0.01 compared with E2-stimulated
values at corresponding time point. D, Western blot analysis of phospho-ERK1/2 MAPK (Thr202/Tyr204) and total ERK1/2 MAPK was performed
on SKBR3 cells treated with either vehicle (0) or E2 (10 nM), with or without CRM197 (200 ng/ml) at the indicated time points. Total cPLA2 or
ERK1/2 was used for protein level normalization as appropriate.
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levels of proliferative eicosanoids (31, 33). Recent studies
have focused on the regulatory mechanisms controlling
the activity of COX-2 during carcinogenesis. These stud-
ies have provided the rationale for the use of nonsteroidal
antiinflammatory drugs (such as indomethacin and flur-
biprofen) and specific COX inhibitors (such as celecoxib
and nimesulide) as chemotherapeutic agents. Despite
their efficacy in slowing the progression of malignancy
(58), these therapies are often associated with detrimental
side effects including gastrointestinal bleeding and car-
diovascular toxicity. Other components of the AA-based
signaling pathway have been proposed as potential tar-
gets for chemoprevention and therapy, including cPLA2,
and therefore, a better understanding of the precise
mechanism underlying the activation of cPLA2 in
breast cancer and its role in proliferation would en-
hance the development of specific pharmacological
strategies for the treatment of breast carcinoma and
also other malignancies.
We have previously shown that cPLA2 is expressed in
the MCF-7 breast carcinoma cell line and is rapidly acti-
vated after treatment with physiological concentrations
of E2 (39). In this present study, we investigated the mo-
lecular mechanism of E2-induced cPLA2 activation in
breast cancer cell lines that differentially express ER and
HER2. In ER-positive, HER2-negative MCF-7 cells, E2
elicited a biphasic activation of cPLA2 that was driven
by trans-activation of EGFR resulting in activation of the
ERK1/2MAPK cascade. Evidence of a synergism between
EGFR and eicosanoid signaling has been described in
other experimental systems. EGFR is required for the
phosphorylation of cPLA2 induced by neurotensin and
EGF in prostate cancer cells (59), and a correlation has
been found between COX-2 activity and EGFR activity in
breast cancer (12, 60). We found that the initial ERK1/2
activation and downstream phosphorylation of cPLA2
in response to E2 was dependent on EGFR trans-activa-
tion in MCF-7 cells, through MMP-dependent release of
HB-EGF and the formation of EGFR/HER2 heterodimers.
The MMP inhibitor GM6001, the HB-EGF inhibitor
CRM197, and the EGFR/HER2 inhibitor AG825 also
blocked the phosphorylation of cPLA2 induced by E2 in
this experimental model. E2-induced ERK1/2 activation
in breast cancer cells can bemediated by direct interaction
of ER with the nonreceptor tyrosine kinase c-Src to acti-
vate Ras. E2 also down-regulates MAPK phosphatase 1
(MKP-1) leading to up-regulation of ERK1/2 activity
within 10 min of treatment (61). This present study sug-
gests that E2 signals through c-Src-dependent, EGFR
trans-activation to promote the early phase of ERK1/2
phosphorylation and subsequent cPLA2 activation
within 1 min, whereas the later phase of cPLA2 activa-
tion after 5–10 min is largely driven by EGFR-indepen-
FIG. 8. Involvement of ER isoforms and GPR30 in mediating the effects of E2 in SKBR3 cells. Panel A, Western blot analysis of total ER was
performed on SKBR3 cells treated with either vehicle (0) or E2 (10 nM) for 24 h and on untreated MCF-7 cells. The different isoforms are indicated
at their respective molecular weight. Samples were also probed for c-Fos as a positive control for E2 treatment because E2 was reported to up-
regulate c-Fos in the SKBR3 cell line (71). -Actin was used for protein level normalization. Panel B, Structure of the 66-kDa wild-type ER and the
two splice variants ER36 and ER46 lacking the N-terminal A/B domain. The different domains (A–F) and amino acid sequence numbers are
indicated. An arrow indicates the epitope recognized by the ER antibody used in this study (adapted from Ref. 51). Panel C, MTT cell growth
assay was performed on SKBR3 cells treated with either vehicle or E2 (10 nM) with or without ICI (10 M), tamoxifen (10 M), or G1 (100 nM) for
48 h. Data are mean values  SE of three independent experiments.
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dent mechanisms through ER-mediated ERK1/2 phos-
phorylation but which is still c-Src dependent.
Approximately 25–30% of human breast cancers dis-
play overexpression or gene amplification of HER2, and
its increased expression correlates with poor clinical out-
come and with resistance to endocrine therapy (25, 62).
EGFR is also overexpressed in 50% of breast tumors and
correlates with resistance to hormonal therapy (25). In
these tumors, the cross talk between ER and EGFR/HER2
signaling pathways results in a positive feedback cycle of
cell survival stimuli. HER2 has the strongest catalytic ac-
tivity of the four members of the EGFR family, and
HER2-containing heterodimers have the greatest capac-
ity for inducing intracellular signaling (46). HER2 is also
less sensitive to inactivating signals, and its recruitment
into heterodimeric signaling complexes leads tomore sus-
tained signaling responses. In the MCF-7 cell line, E2
rapidly promoted an increased dimerization of EGFR
with HER2, which was coupled to increased phosphory-
lation of EGFR but not of HER2. A correlation between
overexpression of COX-2 and HER2 gene amplification
in breast cancer was previously reported byRistima¨ki and
colleagues (7). This was subsequently confirmed by the
finding that HER2 abundance and ac-
tivity determines Cox-2 gene expres-
sion (12). This present study is the
first report of a correlation between
cPLA2 and HER2 overexpression in
a breast cancer cell line. Western blot
analysis of phosphorylated cPLA2
showed a constitutive basal activation
of cPLA2 in SKBR3 cells that was fur-
ther increased after E2 treatment. In
contrast to MCF-7 cells, the E2-in-
duced activation of cPLA2 in SKBR3
cells was entirely dependent on EGFR
trans-activation signaling to ERK1/2.
SKBR3 cells are ER negative but do
express GPR30, which binds to E2
and activates MAPK through MMP-
mediated EGFR trans-activation (42).
The selective GPR30 agonist G1 and
ICI both mimicked the effect of E2
and rapidly stimulated the phos-
phorylation of cPLA2. Inhibition of
EGFR trans-activation by CRM197
and AG825 blocked the E2-induced
activation of ERK and cPLA2 at all
time points analyzed.
If constitutive overexpression of
HER2 were the driver for the in-
creased expression and activation of
cPLA2, then inhibition or down-reg-
ulation of HER2 would also suppress cPLA2. Treat-
ment of SKBR3 cells with the anti-HER2 monoclonal
antibody herceptin in combination with E2 treatment
down-regulated the phosphorylation of both HER2 and
cPLA2, without affecting HER2 or cPLA2 protein ex-
pression levels. Treatment with either herceptin or E2
alone did not elicit any change in the phosphorylation
state of either HER2 or cPLA2, suggesting a synergism
between herceptin action and the presence of estrogen.
When HER2 protein expression was down-regulated us-
ing siRNA, cPLA2 protein basal expression and phos-
phorylation were also diminished. This supports the hy-
pothesis that HER2 overexpression drives constitutive
cPLA2 expression and activation in ER-negative breast
carcinoma cells. cPLA2 controls cell proliferation in
both normal and malignant thyroid epithelial cells (63,
64), and other reports indicate that cPLA2 can mediate
proliferation in human umbilical vein endothelial cells
(65) and also in prostate cancer cells (5). The general
PLA2 inhibitor quinacrine reduced both basal and E2-
induced cell growth in MCF-7 cells (66), whereas this
present study demonstrates that more specific pharmaco-
FIG. 9. Pharmacological inhibition of cPLA2 decreases E2-induced cell growth and increases
apoptosis and necrosis in both MCF-7 and SKBR3. Panel A, MTT cell growth assay was
performed on MCF-7 treated with either vehicle [control (C)] or E2 (10 nM) with or without ICI
(10 M) or the specific cPLA2 inhibitor (50 nM), and (panel B) on SKBR3 treated with either
vehicle (C) or E2 (10 nM) with or without the monoclonal HER2 antibody herceptin (20 mg/ml)
or the cPLA2 inhibitor (50 nM). Data are mean values  SE. *, P  0.01 compared with
vehicle-treated control; **, P  0.01 compared with E2 stimulation. Panel C, An ELISA to
detect oligonucleosomes in the cytoplasm or in the cell culture medium was performed on
both MCF-7 and SKBR3 treated with the cPLA2 inhibitor (50 nM) or ICI (10 mM) or herceptin
(20 g/ml) for 48 h. Data are expressed as percent increase of both apoptosis and necrosis
compared with vehicle-treated controls.
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logical inhibition of cPLA2 reduced E2-induced cell pro-
liferation of both ER-positive (MCF-7) and ER-negative
(SKBR3) breast cancer cells. cPLA2 antagonism in the
absence of E2 inhibited MCF-7 but not SKBR3 cell
growth. This may reflect the lower basal levels of cPLA2
activity in the HER2-negative MCF-7 cells, which makes
them more sensitive to antagonism of both the homeo-
static function of cPLA2 as well as its contribution to
E2-induced cell proliferation. For both cell lines, the re-
duced cell growth was at least in part due to an increase in
cell death, because the cPLA2 inhibitor induced both ap-
optosis and necrosis. The increase in apoptosis could ex-
plain why the levels of cell growth in MCF-7 cells fell
below the basal level of control when cells are treatedwith
the inhibitor, either alone or in combination with E2.
This study demonstrates a novel role for the rapid,
E2-induced trans-activation of EGFR/HER2 heterodimers
in promoting ERK1/2-induced phosphorylation and acti-
vation of cPLA2 in breast cancer cells that differentially
express ER and EGFR/HER2 receptors. HER2 overex-
pression is a well characterized prognostic marker for
invasive breast cancer that is associated with loss of ER
expression and resistance to antiestrogen therapy. Our
data suggest that HER2 overexpression drives increased
cPLA2 expression and constitutive activation, although
loss or inhibition of HER2 can reduce the expression and
activation of cPLA2. In breast cancer cells lacking ER,
E2 can increase basal activation of cPLA2 by trans-acti-
vating EGFR/HER2, possibly via GPR30. As a conse-
quence, cPLA2 may contribute to proliferative E2 sig-
naling in tumors that are ER negative and resistant to
endocrine therapy. E2 exerts a proliferative effect in
breast cancer cells through ER and via EGFR/HER2 in
ER-negative tumors. Lipid mediators produced through
cPLA2 activation could play an important role in medi-
ating proliferation of both endocrine-sensitive and endo-
crine-resistant breast cancer cells. Our data show that
pharmacological inhibition of cPLA2 reduced cell growth
in vitro through increases in apoptotic and necrotic cell
death in both ER-positive and ER-negative cells. Thera-
peutic strategies to target the eicosanoid signaling path-
way have focused mainly on COX-2 inhibition, which
results in adverse side effects on the cardiovascular sys-
tem. This study identifies cPLA2 as a potential, alterna-
tive target for therapeutic intervention in breast cancer.
Materials and Methods
Cell culture
MCF-7, UACC 893, and HCC38 breast carcinoma cells
(American Type Culture Collection, Teddington, UK) were rou-
tinely grown in Eagle’s MEM, Leibovitz L-15, or RPMI 1640
(Sigma-Aldrich, Tallaght, Ireland) culturemedium, respectively,
supplemented with 2 mM L-glutamine, 50 U/ml penicillin, 50
g/ml streptomycin and 10% fetal bovine serum (FBS) (GIBCO,
Paisley, UK). SKBR3 (American Type Culture Collection),
MDA-MB-231, and BT474 breast carcinoma cell lines (Dr. R. J.
Santen, University of Virginia School of Medicine, Charlottes-
ville, VA) were maintained in DMEM/F12 (Sigma-Aldrich) sup-
plemented with nonessential amino acids, 2 mM L-glutamine,
100 g/ml gentamicin, and 10% FBS. All cell lines were incu-
bated in a humidified atmosphere of 5% CO2 at 37 C with the
exception of the UACC 893 cell line, which was maintained at
atmospheric CO2 concentration. For the purpose of experi-
ments, cells were seeded in six-well plates or 10-cm-diameter
dishes at 80% confluency and then serum starved for 48 h be-
fore treatment at 100% confluency as indicated.
Reagents and antibodies
E2 was purchased from Sigma-Aldrich and dissolved in eth-
anol before being diluted in cell culture medium to a final con-
centration of 10 nM. The GPR30-specific agonist G1, the MEK
inhibitor PD98059, the c-Src inhibitor PP2, the matrix metallo-
proteinase inhibitorGM6001, and the specific cPLA2 inhibitor
N-c-3-[4-(2,4-dioxothiazolidin-5-ylidenemethyl)-phenyl]
acrylamide,HCl (67)were obtained fromCalbiochem (Notting-
ham, UK) and dissolved in dimethylsulfoxide (DMSO) (the
cPLA2 inhibitor was dissolved in 75% acetic acid). The HER2/
EGFR inhibitor AG825 and the ER inhibitors ICI and tamox-
ifen were purchased from Tocris (Avonmouth, UK) and dis-
solved in DMSO or methanol, respectively. The D2189 [Glu52]
diphtheria toxin CRM197 was obtained from Sigma-Aldrich
and diluted in distilled water to 1 mg/ml. Herceptin (Roche,
Clairecastle, Ireland) was diluted in PBS to 10 g/ml. The bicin-
choninic acid protein assay was purchased from Pierce
(Northumberland, UK). The Rainbow molecular weight
marker, the ECL chemiluminescence reagents, and hyperfilm
were from Amersham Bioscience (Little Chalfont, UK). The
MTT cell growth assay was from Promega (Southampton, UK).
The apoptosis assay was from Roche Applied Science (Burgess
Hill, UK). The anti-ER, anti-cPLA2, anti-HER2, anti-
phospho-HER2 (Tyr1221/1222), anti-EGFR, anti-phospho-
EGFR (Tyr845), anti-p44/42 MAPK, anti-phospho-p44/42
MAPK (Thr202/Tyr204), the anti-c-Fos, the antimouse IgG
horseradish peroxidase conjugate antibodies, and the phospho-
HER2 (Tyr1221/1222) ELISA kit were from Cell Signaling
Technology (Hitchin, UK). The anti-phospho-cPLA2 antibody
was from Santa Cruz Biotechnology (Heidelberg, Germany).
The antirabbit IgG horseradish peroxidase conjugate and the
anti--actin antibodies were from Sigma-Aldrich. All other
chemical reagents used were purchased from Sigma-Aldrich,
unless otherwise specified.
Immunoprecipitation and Western blotting
Cells were treated with 10 nM E2 or vehicle control for the
indicated times. Preincubation with the indicated inhibitors was
performed as described. Cells were then transferred onto ice,
washed twice with ice-cold PBS, and then ultrasonicated in lysis
buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1
g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, complete
mini EDTA-free protease inhibitor mixture tablets (one tablet
per 10ml lysis buffer; Roche) and phosphatase inhibitors]. Sam-
ples were clarified by centrifugation at 13,000 rpm for 15 min,
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and supernatants were collected and stored at 80 C for sub-
sequent analysis. Total protein concentration was quantified
using the bicinchoninic acid assay (68). For immunoprecipita-
tion, equal amounts of soluble cell extracts were incubated with
2 g of either anti-EGFR or anti-HER2 antibody for 16 h at 4 C
with rotation. Washed EZ-view Red Protein A Beads (Sigma-
Aldrich) were combined with samples and incubated for 1 h at 4
C on a rotor. Complexes were centrifuged at 13,000 rpm for 3
min, the supernatants were removed, and pelleted beads were
washed five times in lysis buffer. Finally, samples were resus-
pended in 20l 2 Laemmli sample buffer (Sigma-Aldrich) and
boiled for 5 min at 95 C. For nonimmunoprecipitated samples,
total cell extracts were combined with equal amounts of 2
Laemmli sample buffer and heated for 5 min at 95 C.
Solubilized proteins (40 g) were resolved by SDS-PAGE on
6% (EGFR, HER2, cPLA2, and COX-2) or 10% (ERK1/2) gels
(100 V, 90min). Proteins were then transferred to nitrocellulose
membranes (15 V, 45 min to 2 h) with a Trans-Blot SD system
(Bio-Rad, Hemel Hempstead, UK).Membranes were blocked in
TBS with 0.1% Tween 20 and 5% nonfat dry milk for 1 h at 25
C, incubated with the indicated primary antibody for 16 h at 4
C, and probed with the appropriate secondary antibody for 1 h
at 25 C.Membranes were washed three times in TBS with 0.1%
Tween 20 at 25 C, and antibody reaction was visualized by
enhanced chemiluminescence on an autoradiographic film.
Membranes were stripped with Restore Western blot stripping
buffer (Pierce Chemical Co., Rockford, IL) for 10 min at 25 C
and reprobed with the anti--actin or total target protein anti-
body as indicated to normalize densitometry data for gel load-
ing. Tubulin was used in normalization of the cell line compar-
ison (Fig. 6B) due to large variation in -actin expression
between the cell lines.
RNA isolation and RT-PCR analysis
Total RNA was extracted from the cell lines indicated using
the RNeasy mini kit (QIAGEN, Crawley, UK) according to the
manufacturer’s instructions. RNA was finally eluted in diethyl-
pyrocarbonate-treated water (30 l) and stored at 80 C. The
quantity and quality of the extracted RNA was confirmed by
absorption measurements at 260 and 280 nm. Single-strand
cDNAwas synthesized using the ImProm II reverse transcriptase
kit (Promega). cDNA was quantified and corrected for loading
into RT-PCR mixes. GoTaq polymerase mix (Promega) was
used in the PCR amplification. Touchdown PCR was used to
amplify cDNA for the indicated number of cycles and annealing
temperature range for each primer set used. The RT-PCR prod-
uct was analyzed on a 1% Tris acetate-EDTA agarose gel and
visualized using a UV light source. The abundance of target
mRNA detected was normalized in comparison with the glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) internal con-
trol. The sequences for gene-specific forward and reverse prim-
ers were designed using the OligoPerfect Designer software
program (Invitrogen), unless a different source is specified. Se-
quences were as follows: for ErbB2/HER2 (GeneID 2064), 5-
CCATAACACCCACCTCTGCT-3 (forward) and 5-ACTG-
GCTGCAGTTGACACAC-3 (reverse), 20 cycles at 58–68 C;
for EGFR (GeneID 1956), 5-ATGTCCGGGAACACAAA-
GAC-3 (forward) and 5-TTCCGTCATATGGCTTGGAT-3
(reverse), 40 cycles at 56 C (69); for cPLA2 (PLA2G4A,
GeneID 5321), 5-ACGTTTCAGAGCTGATGTTT-3 (for-
ward) and 5-CTTCCAGCATCTTCATTTTC-3 (reverse), 30
cycles at 52–62 C; for COX-2 (PTGS2, GeneID 5743), 5-
TGAAACCCACTCCAAACACA-3 (forward) and 5-GAGA-
AGGCTTCCCAGCTTTT-3 (reverse), 40 cycles at 58–63 C;
and for GAPDH (GeneID 2597), 5-GTCATCATCTCTGC-
CCCCTCTGC-3 (forward) and 5-CGACGGCTGCTTCAC-
CACCTTCT-3 (reverse), 14 cycles at 52 C (Table 1).
For quantitative real-time PCR, 2 l cDNA was loaded in a
96-well plate with SYBR Green I Master mix (Roche), and am-
plification was carried out in a LightCycler 480 (Roche) as fol-
lows: a preincubation step at 95 C for 10 min was followed by
45 cycles of denaturation at 95 C for 10 sec, annealing at 60 C
for 10 sec, and elongation at 72 C for 10 sec. Efficiencies for
each primer set were calculated from the PCR kinetic curve
using the linear regression method with LinRegPCR software
(70) and used to measure relative quantification of gene expres-
sion with the comparative cycle threshold method. All samples
were normalized for 18S rRNA expression levels. The sequences
for 18S primers were 5-GTCCCCCAACTTCTTAGAG-3 (for-
ward) and 5-CACCTACGGAAACCTTGTTAC-3 (reverse).
Cell growth and apoptosis assays
Reduction ofMTT by mitochondrial respiration was used to
measure cell growth. Cells were harvested, counted in a
Neubauer chamber, and seeded in a 96-well plate at 105 cells per
well in medium containing 2% charcoal-stripped FBS. After
TABLE 1. Primer sequences
Gene name Primer sequences (5–3) Product size (bp) Number of cycles Annealing temperature (°C)
ErbB2-HER2
Forward CCATAACACCCACCTCTGCT 194 20 58–68
Reverse ACTGGCTGCAGTTGACACAC
EGFR (80)
Forward ATGTCCGGGAACACAAAGAC 351 40 56
Reverse TTCCGTCATATGGCTTGGAT
cPLA2
Forward ACGTTTCAGAGCTGATGTTT 352 30 52–62
Reverse CTTCCAGCATCTTCATTTTC
COX-2
Forward TGAAACCCACTCCAAACACA 187 40 58–63
Reverse GAGAAGGCTTCCCAGCTTTT
GAPDH
Forward GTCATCATCTCTGCCCCCTCTGC 444 14 52
Reverse CGACGGCTGCTTCACCACCTTCT
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16 h, cells were stimulated with 10 nM E2 or vehicle control,
with or without the indicated inhibitors. Stimulation was re-
peated after 48 h and carried out for a total 96 h before per-
forming the growth assay, in which cells were incubated with 1
mg/ml MTT for 4 h at 37 C in a humidified atmosphere con-
taining 5% CO2. The reaction was stopped by the addition of a
DMSO solution and solubilization of formazan crystals was
allowed for 2 h at 37 C. Absorbance was measured at 570 nm
using a Multiskan EX plate reader (Thermo Scientific, Northum-
berland, UK). A photometric enzyme immunoassay (Roche) was
used for the quantitative determination of cytoplasmic histone-
associated DNA fragments to measure cell death. Cells were
seeded on a 96-well plate at 105 cells per well in medium con-
taining vehicle or the indicated inhibitors and incubated for
48 h. Medium was collected and cells lysed for 30 min at 25 C;
then both cell lysates and medium supernatants were used for
the ELISA following the manufacturer’s instructions, and ab-
sorbance was measured at 405 nm.
cPLA2 enzymatic activity
MCF-7 and SKBR3 cells were lysed as previously described,
and lysates were incubated with 5 M bromoenol lactone and
200 M thioetheramide-phosphatidylcholine (Cayman Europe,
Tallinn, Estonia) for 15 min at 25 C to inhibit either Ca2-
independent intracellular PLA2 or Ca
2-dependent secretory
PLA2, respectively. Samples were then incubated with arachido-
noyl thio-phosphatidylcholine using a cPLA2 assay kit (Cay-
man) according to themanufacturer’s directions. Briefly, 60min
after incubation, samples were mixed with a solution of 5,5-
dithio-bis2-nitrobenzoic acid/EGTA to detect free thiols re-
leased by hydrolysis of arachidonoyl thioester bonds by cPLA2.
Absorbances were measured at 405 nm using a Multiskan EX
iplate reader (Thermo Scientific). Enzymatic activity was calcu-
lated using the 5,5-dithio-bis2-nitrobenzoic acid extinction co-
efficient of 10 mM1.
RNA silencing
A pool of four different siRNA specific for ErbB2 (NCBI gene
ID 2064) was purchased from Dharmacon (Lafayette, CO). Se-
quences were as follow: siRNA 1, GGACGAAUUCUGCA-
CAAUG; siRNA 2, GACGAAUUCUGCACAAUGG; siRNA 3,
CUACAACACAGACACGUUU; and siRNA 4, AGACGAAG-
CAUACGUGAUG. A nontargeting siRNA with at least four
mismatches with all known human genes (DharmaconD-001210-
01)was used as negative control. All siRNAswere resuspended to
a 20 M concentration in a buffer containing 60 mM KCl, 6 mM
HEPES (pH 7.5), and 0.2 mM MgCl2. SKBR3 cells were trans-
fected with 100 nM siRNA using DharmaFECT (Dharmacon)
and silencing ofHER2 expressionwas assessed byWestern blot-
ting over a time course of 24–96 h. Maximal silencing (65%)
was obtained 72 h after transfection; cells were then lysed, and
Western blotting for HER2 and cPLA2 was performed as previ-
ously described.
Statistical analysis
Densitometric analysis of polyacrylamide and agarose gels
was performed using GeneTools software (Syngene, Cam-
bridge, UK). Statistical analysis of the data was performed using
paired Student’s t test for analysis between two groups. One-
way ANOVA was used for multiple analyses of more than two
groups. P values 0.05were considered statistically significant.
Data are expressed as mean  SE of the indicated number of
experiments (at least three different experiments performed in
duplicate).
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